adult T-cell leukaemia/lymphoma (ATLL)
cofactors, 147
prevention, 147
subtypes of, 147
tax gene, 146
aflatoxin, 112–13, 115
AIDS-defining illness, 145, 148
alcohol, 112, 115
amplification/deletion, chromosome abnormality, 50
anal cancer
cofactors, 131
MSM, 131
prevention, 131–2
aneuploidy, chromosome abnormality, 49–50
angiogenesis, 54–5
apoptosis, 45–6
ATLL see adult T-cell leukaemia/lymphoma
Bethesda classification, 126–7
biological background, IAC
carcinogenesis mechanisms, 62–6
carcinogenesis, multi-hit theory of, 60–61
cell physiology alterations, 57
direct and indirect carcinogenesis, 61–2
multi-stage carcinogenesis, 58–60
oncogenes and tumour suppressor genes, 58
transmissible tumours, 66
bladder cancer, schistosome species, 177–8
body fluids (non-sexual transmission)
blood transfusion, 75
iatrogenic spread of, 75
breast cancer, 187
Burkitt’s lymphoma (BL), 22, 95–6
cancer aetiology, criteria
Bradford Hill criteria, 36–7
Evans–Mueller guidelines, 35
Koch’s postulates, 34–5
cancer gene, types
angiogenesis, 54–5
DNA repair genes, 54
oncogenes, 52–3
tumour suppressor genes, 53
canine transmissible venereal tumour (CTVT), 66
carcinogenesis mechanisms, IAC
causation vs. association, 65–6
episomal DNA, 64–5
latent infections, 63
viral genetic material integration, 64
carcinogenesis, multi-hit theory, 60–61
cell cycle, molecular biology
Hayflick limit, 48–9
stages in, 48
time for, 48
cervical cancer
cofactors, 127–8
prevention, 128–30
stages of, 126–7
cervical infection, epidemiology, 25
Chlamydia psittaci, 188
cholangiocarcinoma, liver flukes, 184
chromosome abnormality, types
  qualitative anomalies, 51
  quantitative anomalies, 49–51
Clonorchis sinensis, 182–3
cofactors, 1–2
  anal cancer, 131
  ATLL, 147
  bladder cancer, 178
  cervical cancer, 127–8
  gastric cancer, 166
  for HCC, 112–13
  head and neck cancer, 132
  multiple myeloma, 99–100
  penile cancer, 130–131
  PTLD, 96–7
colon cancer, 187
confounding element, carcinogenesis mechanisms, 65
cytotoxicity-associated antigen (CagA), 164
direct and indirect carcinogenesis
  inflammation and cancer, 61–2
  latency and penetrance, 62
DNA repair genes, 54
episomal DNA, 64–5
Epstein–Barr virus (EBV), 2
  associated malignancies, 94–5
  epidemiology of, 21–3
  IARC status, 94
  organism, 94
  primary prevention, 84
extra-nodal NHL, 188
extremophiles, 161
field cancerization, 62

geographical variation in, incidence rates of, 20–21
Helicobacter pylori, 29–30
hepatitis viruses, 23–4
HTLV-1, 26
human herpesvirus 8/Kaposi sarcoma herpesvirus, 26–8
human papillomaviruses, 24–6
liver flukes, 33–4
Merkel cell polyomavirus, 29
Schistosoma species, 30–33
simian virus 40, 28–9
gynaecophoric canal, schistosome species, 175–6

Hayflick limit, cell cycle, 48–9
HCC see hepatocellular carcinoma
head and neck cancer
cofactors, 132
  prevention, 132–3
  squamous cell cancers (HNSCC), 132
Helicobacter pylori
cofactors, 162, 166
  extremophile, 161
global burden, 29–30
  historical background, 162–4
  infections, 162
  MALToma, 165
microbiology of, 164
  oesophageal cancer, 166
  prevention, 167
  primary prevention, 78–9
  proximal gastric cancers, 166
  stomach cancer, 165
hepadnavirus, 107
hepatitis B (HBV)
  HDV and, 106
  IARC status, 107–8
  immune response, 106–7
hepatitis C (HCV)
  IARC status, 108–10
  immune response, 107
  malignancies associated
    with, 112
  non-Hodgkin lymphoma (NHL), 111
hepatitis D (HDV)
  IARC status, 110
  as satellite agent to HBV, 106
hepatitis viruses
  cofactors, 112–13
  epidemiology of, 23–4
  liver cirrhosis, 106–7
  prevention, 113–15
  primary prevention, 80–82
  transmission, 106
hepatocellular carcinoma (HCC), 110–111
herpesviridae see herpesviruses
herpesviruses, 93–4
  Burkitt’s lymphoma (BL), 95–6
  Epstein–Barr virus, 94–5
  Hodgkin’s lymphoma (HL), 95
  Kaposi sarcoma, 98
  KSHV/HHV-8, 97–8
  multiple myeloma, 99–101
  plasmablastic multi-centric Castleman’s disease, 99
  primary effusion lymphoma (PEL), 99
  PTLD, 96–7
highly active anti-retroviral therapy (HAART), 146, 148–9
historical background
  antiquity of, 5
  Burkitt’s lymphoma, tumours and, 11–13
  false dawns and delayed recognition, 9–11
  Graeco-Roman literature, 6–7
  Kanam mandible, 6
  oncogenes, retroviruses and, 14–15
  papyruses, 6
  stomach and, 13–14
  Hodgkin’s lymphoma (HL), 95
  human herpesvirus 8 (HHV-8), 97–8 see also Kaposi sarcoma herpesvirus (KSHV)/human herpesvirus 8 (HHV-8)
human immunodeficiency virus (HIV)
  AIDS-defining illness, 145
  cancers in, relative risk of, 148
  epidemiological data, 144–5
  lentivirus, features of, 144
  primary prevention, 83
  transmission routes, 146
human papillomavirus (HPV), 1
  anal cancer, 131–2
  biology, 122
  cervical cancer, 126–30
cervical infection, 25
  epidemiology of, 24–6
  epidemiology/transmission, 124–5
  head and neck cancer, 132–3
  organism, 121–5
  penis, 130–131
  sites, 25–6
  squamous epithelium, 122–4
human T-cell lymphotropic virus-1 (HTLV-1)
  ATLL, 146–7
  epidemiology of, 26
  screening of, 144
  transmission, 143
inflammation and cancer, 61–2
International Agency for Research on Cancer (IARC), 175, 182, 184
hepatitis B (HBV), 107–8
hepatitis C (HCV), 108–10
hepatitis D (HDV), 110
liver flukes, 33
Schistosoma species, 32
intrafamilial spread, 72–3
inversion, chromosome abnormality, 51
Kanam mandible, 6
Kaposi sarcoma, 98
Kaposi sarcoma herpesvirus (KSHV)/human herpesvirus 8 (HHV-8)
  associated malignancies, 98
  classic, 26–7
  endemic (African), 27
  epidemic, 28
  epidemiology of, 26–8
  IARC status, 98
  iatrogenic, 27
  organism, 97–8
  primary prevention, 84
katayama, 177
liver flukes
  cholangiocarcinoma, 184
  C. sinensis and O. viverrini, 182–3
  global burden and, 33–4
  prevention, 184
  transmission, 183
loss of heterozygosity/imprinting, 50–51
lung cancer, 188
lymphoproliferative disorders, 111–12

Merkel cell polyomavirus (MCP), 156
global burden and, 29
molecular biology, of cancer
apoptosis, 45–6
cancer gene, types of, 51–5
cell cycle, 47–9
chromosome abnormality, types of, 49–51
malignant cells, features of, 44–5
malignant clone, features of, 44
tissues types, 46
transformation of, 49, 55
mucosal-associated lymphoid tissue
(MALToma) lymphoma, 165, 188
multi-centric Castleman’s disease
(MCD), 99
multi-hit theory of carcinogenesis, 60–61
multiple myeloma
cofactors, 99–100
prevention, 100–101
multi-stage carcinogenesis, 58–60
neck cancer, 132–3
non-AIDS-defining malignancies
cofactors, 148
prevention, 148–9
non-Hodgkin lymphoma (NHL), 111
oncogenes, 14–15, 52–3, 58
Opisthorchis viverrini, 182–3
papillomavirus, 82–3 see also human
papillomavirus (HPV)
penile cancer
cofactors, 130–131
forms of, 130
prevention, 131
plasmablastic multi-centric Castleman’s
disease see multi-centric Castleman’s
disease (MCD)
polyomaviruses
MCP, 156
organisms, 155
SV 40, 155–6
post-transplant lymphoproliferative
disorder (PTLD), 76–7
cofactors, 96–7
prevention, 97
prevention see primary prevention;
secondary prevention
primary effusion lymphoma (PEL), 99
primary prevention, 3, 70–71
Epstein–Barr virus (EBV), 84
Helicobacter pylori, 78–9
hepatitis viruses, 80–82
human immunodeficiency virus, 83
KSHV/HHV-8, 84
papillomavirus, 82–3
schistosome species, 78
virus infections, 79–80
prostate cancer, 187–8
proximal gastric cancers, 166
public health considerations and
prevention
body fluids (non-sexual transmission),
75–6
intrafamilial spread, 72–3
non-sexual social contacts, 73
options for, 77
primary see primary prevention
PTLD, 76–7
sexual transmission, 73–5
spreading mechanisms, 71
vertical transmission, 72
retroviruses, 14–15
AIDS-defining malignancies, 148
features, 142
genomes, 142
HIV, 144–8
HTLV-1, 142–4, 146–7
non-AIDS-defining malignancies,
148–9
organisms, 141–2
Schistosoma haematobium, 30–31, 175,
177–8
Schistosoma japonicum, 175, 177
Schistosoma mansoni, 175, 177
schistosome species
bladder cancer, 31, 177–8
cofactors, 178
global burden and, 30–33
IARC, 32
life cycles, 30
schistosome species (cont’d)
   organism, 175–7
   prevention, 178–9
   primary prevention, 78
schistosomiasis-associated bladder cancer
   (SABC), 178
secondary prevention, 3, 70–71
sexual transmission, 73–5
simian virus 40 (SV 40), 155–6
   global burden and, 28–9
squamous cell carcinoma (SCC), 177–8
squamous epithelium
   stratified squamous epithelium (SSE), 123
   transformation zones, 123–4
squamous metaplasia, 178
stomach cancer, 165
swimmer’s itch, 177

transitional cell carcinoma (TCC)
   see urothelial cancer
translocations, chromosome
   abnormality, 51
transmissible tumours, 66
tumour suppressor genes, 53, 58
unconfirmed associations, 187–9
urothelial cancer, 177
urothelium/transitional epithelium, 177
vaccines, 2–3
vertical transmission, 72
viral genetic insertion, chromosome
   abnormality, 50
virus infection
   hepatitis viruses, 113–14
   primary prevention, 79–80